Medicina
Facultat
United States Food and Drug Administration
Silver Spring, Estados UnidosPublicacions en col·laboració amb investigadors/es de United States Food and Drug Administration (21)
2021
-
Core Outcome Measures for Trials in People with Coronavirus Disease 2019: Respiratory Failure, Multiorgan Failure, Shortness of Breath, and Recovery
Critical Care Medicine, Vol. 49, Núm. 3, pp. 503-516
-
Drug development for Autism Spectrum Disorder (ASD): Progress, challenges, and future directions
European Neuropsychopharmacology, Vol. 48, pp. 3-31
-
Inclusion of Adolescents in Adult Clinical Trials: Report of the Institute for Advanced Clinical Trials for Children’s Pediatric Innovation Research Forum
Therapeutic Innovation and Regulatory Science, Vol. 55, Núm. 4, pp. 773-778
-
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group
npj Breast Cancer, Vol. 7, Núm. 1
-
Viewpoint of a WHO Advisory Group Tasked to Consider Establishing a Closely-monitored Challenge Model of Coronavirus Disease 2019 (COVID-19) in Healthy Volunteers
Clinical Infectious Diseases, Vol. 72, Núm. 11, pp. 2035-2041
2019
-
Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial
The Lancet Respiratory Medicine, Vol. 7, Núm. 11, pp. 951-963
-
Report of the European Society of Cardiology Cardiovascular Round Table regulatory workshop update of the evaluation of new agents for the treatment of acute coronary syndrome: Executive summary
European Heart Journal: Acute Cardiovascular Care, Vol. 8, Núm. 8, pp. 745-754
2018
-
Allergen manufacturing and quality aspects for allergen immunotherapy in Europe and the United States: An analysis from the EAACI AIT Guidelines Project
Allergy: European Journal of Allergy and Clinical Immunology, Vol. 73, Núm. 4, pp. 816-826
-
Challenges in the implementation of EAACI guidelines on allergen immunotherapy: A global perspective on the regulation of allergen products
Allergy: European Journal of Allergy and Clinical Immunology, Vol. 73, Núm. 1, pp. 64-76
-
Radiotherapeutic implications of the updated ICRP thresholds for tissue reactions related to cataracts and circulatory diseases
Annals of the ICRP, Vol. 47, Núm. 3-4, pp. 196-213
2017
-
Neutral evolution of drug resistant colorectal cancer cell populations is independent of their KRAS status
PLoS ONE, Vol. 12, Núm. 10
-
Optimizing research to speed up availability of pediatric antiretroviral drugs and formulations
Clinical Infectious Diseases, Vol. 64, Núm. 11, pp. 1597-1603
2016
2015
-
Distinct Trafficking of Cell Surface and Endosomal TIM-1 to the Immune Synapse
Traffic, Vol. 16, Núm. 11, pp. 1193-1207
-
Implications in medical imaging of the new ICRP thresholds for tissue reactions
Annals of the ICRP, Vol. 44, pp. 118-128
-
Overview of ICRP Committee 3 ‘Protection in Medicine’
Annals of the ICRP, Vol. 44, pp. 24-32
-
Overview of ICRP Committee 3: protection in medicine
Annals of the ICRP, Vol. 45, pp. 25-33
2008
-
Methods of deriving EULAR/ACR recommendations on reporting disease activity in clinical trials of patients withd-heumatoid arthritis
Annals of the Rheumatic Diseases, Vol. 67, Núm. 10, pp. 1365-1373
-
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations
Arthritis Care and Research, Vol. 59, Núm. 10, pp. 1371-1377